These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38499180)

  • 1. Response to Desai et al, "Response to 'Low-dose oral minoxidil for androgenetic alopecia is not associated with clinically significant blood-pressure changes: a retrospective study'".
    Ong M; Lipner SR
    J Am Acad Dermatol; 2024 Jul; 91(1):e9-e10. PubMed ID: 38499180
    [No Abstract]   [Full Text] [Related]  

  • 2. Response to "Low-dose oral minoxidil for androgenetic alopecia is not associated with clinically significant blood-pressure changes: A retrospective study".
    Desai D; Nohria A; Sikora M; Mandal S; Shapiro J; Caplan AS; Garshick M; Lo Sicco K
    J Am Acad Dermatol; 2024 Jul; 91(1):e11-e12. PubMed ID: 38499178
    [No Abstract]   [Full Text] [Related]  

  • 3. Effectiveness and safety of low-dose oral minoxidil in male androgenetic alopecia.
    Jimenez-Cauhe J; Saceda-Corralo D; Rodrigues-Barata R; Hermosa-Gelbard A; Moreno-Arrones OM; Fernandez-Nieto D; Vaño-Galvan S
    J Am Acad Dermatol; 2019 Aug; 81(2):648-649. PubMed ID: 31054970
    [No Abstract]   [Full Text] [Related]  

  • 4. Improvement in androgenetic alopecia (stage V) using topical minoxidil in a retinoid vehicle and oral finasteride.
    Walsh DS; Dunn CL; James WD
    Arch Dermatol; 1995 Dec; 131(12):1373-5. PubMed ID: 7492124
    [No Abstract]   [Full Text] [Related]  

  • 5. Combined treatment with oral finasteride and topical minoxidil in male androgenetic alopecia: a randomized and comparative study in Chinese patients.
    Hu R; Xu F; Sheng Y; Qi S; Han Y; Miao Y; Rui W; Yang Q
    Dermatol Ther; 2015; 28(5):303-8. PubMed ID: 26031764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Controversies in the treatment of androgenetic alopecia: The history of finasteride.
    Andy G; John M; Mirna S; Rachita D; Michael K; Maja K; Aseem S; Zeljana B
    Dermatol Ther; 2019 Mar; 32(2):e12647. PubMed ID: 30253001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effectiveness of adding low-level light therapy to minoxidil 5% solution in the treatment of patients with androgenetic alopecia.
    Faghihi G; Mozafarpoor S; Asilian A; Mokhtari F; Esfahani AA; Bafandeh B; Nouraei S; Nilforoushzadeh MA; Hosseini SM
    Indian J Dermatol Venereol Leprol; 2018; 84(5):547-553. PubMed ID: 30027912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of female pattern hair loss with a combination of spironolactone and minoxidil.
    Hoedemaker C; van Egmond S; Sinclair R
    Australas J Dermatol; 2007 Feb; 48(1):43-5. PubMed ID: 17222303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose oral minoxidil for androgenetic alopecia is not associated with clinically significant blood-pressure changes: A retrospective study.
    Ong M; Do H; Ho B; Lipner SR
    J Am Acad Dermatol; 2024 Feb; 90(2):425-427. PubMed ID: 37839733
    [No Abstract]   [Full Text] [Related]  

  • 10. Randomized clinical trial comparing 5% and 1% topical minoxidil for the treatment of androgenetic alopecia in Japanese men.
    Tsuboi R; Arano O; Nishikawa T; Yamada H; Katsuoka K
    J Dermatol; 2009 Aug; 36(8):437-46. PubMed ID: 19691748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy and tolerability of 5% minoxidil solution (Carexidil®) in male and female androgenetic alopecia: a 6-month open multicentric study].
    Piraccini B; Starace M; Alessandrini A; Guarrera M; Fiorucci MC; Lorenzi S
    G Ital Dermatol Venereol; 2011 Dec; 146(6 Suppl 1):1-8. PubMed ID: 22189834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients.
    Vañó-Galván S; Pirmez R; Hermosa-Gelbard A; Moreno-Arrones ÓM; Saceda-Corralo D; Rodrigues-Barata R; Jimenez-Cauhe J; Koh WL; Poa JE; Jerjen R; Trindade de Carvalho L; John JM; Salas-Callo CI; Vincenzi C; Yin L; Lo-Sicco K; Waskiel-Burnat A; Starace M; Zamorano JL; Jaén-Olasolo P; Piraccini BM; Rudnicka L; Shapiro J; Tosti A; Sinclair R; Bhoyrul B
    J Am Acad Dermatol; 2021 Jun; 84(6):1644-1651. PubMed ID: 33639244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Efficacy of Topical Minoxidil for Non-Scarring Alopecia: A Systematic Review.
    Sung CT; Juhasz ML; Choi FD; Mesinkovska NA
    J Drugs Dermatol; 2019 Feb; 18(2):155-160. PubMed ID: 30794366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective cardiovascular evaluation with 24-hour Holter and 24-hour ambulatory blood pressure monitoring in men using 5-mg oral minoxidil for androgenetic alopecia.
    Sanabria BD; Palmegiani E; Seron AF; Perdomo YC; Miot HA; Müller Ramos P
    J Am Acad Dermatol; 2023 Feb; 88(2):436-437. PubMed ID: 35597386
    [No Abstract]   [Full Text] [Related]  

  • 15. Finasteride treatment may not prevent telogen effluvium after minoxidil withdrawal.
    Tosti A; Iorizzo M; Vincenzi C
    Arch Dermatol; 2003 Sep; 139(9):1221-2. PubMed ID: 12975176
    [No Abstract]   [Full Text] [Related]  

  • 16. Oral minoxidil 7.5 mg for hair loss increases heart rate with no change in blood pressure in 24 h Holter and 24 h ambulatory blood pressure monitoring.
    Sanabria BD; Perdomo YC; Miot HA; Ramos PM
    An Bras Dermatol; 2024; 99(5):734-736. PubMed ID: 38772752
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy and safety of very-low-dose oral minoxidil 1.25 mg in male androgenetic alopecia.
    Jha AK; Sonthalia S; Zeeshan MD; Vinay K
    J Am Acad Dermatol; 2020 Nov; 83(5):1491-1493. PubMed ID: 32492469
    [No Abstract]   [Full Text] [Related]  

  • 18. A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil vs. 3% minoxidil solution in the treatment of male androgenetic alopecia.
    Suchonwanit P; Srisuwanwattana P; Chalermroj N; Khunkhet S
    J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2257-2263. PubMed ID: 29972712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the efficacy of topical minoxidil 5% and adenosine 0.75% solutions on male androgenetic alopecia and measuring patient satisfaction rate.
    Faghihi G; Iraji F; Rajaee Harandi M; Nilforoushzadeh MA; Askari G
    Acta Dermatovenerol Croat; 2013; 21(3):155-9. PubMed ID: 24183218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral minoxidil treatment for hair loss: A review of efficacy and safety.
    Randolph M; Tosti A
    J Am Acad Dermatol; 2021 Mar; 84(3):737-746. PubMed ID: 32622136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.